Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDPH.L Regulatory News (DPH)

  • There is currently no data for DPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - DECHRA PHARMACEUTICALS PLC

3 Oct 2023 14:25

RNS Number : 5621O
Barclays PLC
03 October 2023
 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR

MORE

Rule 8.3 of the Takeover Code (the "Code")

1.

KEY INFORMATION

(a)

Full name of discloser:

 

Barclays PLC.

(b)

Owner or controller of interest and short

 

 

positions disclosed, if different from 1(a):

(c)

Name of offeror/offeree in relation to whose

DECHRA PHARMACEUTICALS PLC

 

relevant securities this form relates:

(d)

If an exempt fund manager connected with an

 

 

offeror/offeree, state this and specify identity of

 

offeror/offeree:

(e)

Date position held/dealing undertaken:

02 Oct 2023

(f)

In addition to the company in 1(c) above, is the discloser making

NO

 

 

 

disclosures in respect of any other party to the offer?

 

 

2.

POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)

Interests and short positions in the relevant securities of the offeror or offeree

 

 

to which the disclosure relates following the dealing(if any)

 

Class of relevant security:

1p ordinary

 

Interests

Short Positions

 

Number

(%)

Number

(%)

(1)

Relevant securities owned

 

 

 

 

 

and/or controlled:

 

 

6,982,776

6.13%

1,923,212

1.69%

(2)

Cash-settled derivatives:

 

 

 

 

 

and/or controlled:

 

 

1,252,001

1.10%

6,882,275

6.04%

(3)

Stock-settled derivatives (including options)

 

 

 

 

 

and agreements to purchase/sell:

 

 

0

0.00%

0

0.00%

 

 

 

 

 

 

 

 

 

TOTAL:

 

 

8,234,777

7.23%

8,805,487

7.73%

(b)

Rights to subscribe for new securities (including directors and other executive

 

 

options)

 

 

 

 

 

 

Class of relevant security in relation to

 

 

 

 

which subscription right exists

 

 

 

 

Details, including nature of the rights

 

 

 

 

concerned and relevant percentages:

 

 

 

 

3.

DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

 

 

 

 

 

Class of relevant

Purchase/sale

Number of

Price per unit

security

 

securities

 

1p ordinary

Purchase

11,369

37.8366Â GBP

1p ordinary

Purchase

9,701

37.9014Â GBP

1p ordinary

Purchase

9,568

37.8197Â GBP

1p ordinary

Purchase

6,108

37.8434Â GBP

1p ordinary

Purchase

5,604

37.8400Â GBP

1p ordinary

Purchase

5,000

37.9189Â GBP

1p ordinary

Purchase

4,813

37.9754Â GBP

1p ordinary

Purchase

4,622

37.8573Â GBP

1p ordinary

Purchase

4,350

37.8652Â GBP

1p ordinary

Purchase

2,768

37.8664Â GBP

1p ordinary

Purchase

2,756

37.7991Â GBP

1p ordinary

Purchase

2,700

37.8586Â GBP

1p ordinary

Purchase

1,552

38.0010Â GBP

1p ordinary

Purchase

1,346

37.8856Â GBP

1p ordinary

Purchase

1,037

38.0015Â GBP

1p ordinary

Purchase

739

37.9037Â GBP

1p ordinary

Purchase

694

37.8437Â GBP

1p ordinary

Purchase

540

37.8154Â GBP

1p ordinary

Purchase

415

37.9312Â GBP

1p ordinary

Purchase

381

37.8057Â GBP

1p ordinary

Purchase

215

37.9400Â GBP

1p ordinary

Purchase

179

37.9000Â GBP

1p ordinary

Purchase

179

37.7400Â GBP

1p ordinary

Purchase

154

37.7600Â GBP

1p ordinary

Purchase

148

37.9600Â GBP

1p ordinary

Purchase

144

38.0600Â GBP

1p ordinary

Sale

35,109

37.8290Â GBP

1p ordinary

Sale

31,184

37.8856Â GBP

1p ordinary

Sale

27,701

37.8695Â GBP

1p ordinary

Sale

21,408

37.8352Â GBP

1p ordinary

Sale

15,741

37.8526Â GBP

1p ordinary

Sale

14,757

37.8400Â GBP

1p ordinary

Sale

4,801

37.8380Â GBP

1p ordinary

Sale

3,842

37.8362Â GBP

1p ordinary

Sale

2,816

37.9030Â GBP

1p ordinary

Sale

1,723

37.8200Â GBP

1p ordinary

Sale

1,495

37.8768Â GBP

1p ordinary

Sale

1,432

37.8392Â GBP

1p ordinary

Sale

154

37.7600Â GBP

1p ordinary

Sale

126

37.8093Â GBP

1p ordinary

Sale

3

37.8366Â GBP

 

 

 

 

 

 

 

 

(b)

Cash-settled derivative transactions

 

Class of

Product

Nature of dealing

Number of

Price per

relevant

description

 

reference

unit

security

 

 

securities

 

1p ordinary

SWAP

Long

154

37.7600Â GBP

1p ordinary

SWAP

Long

1,432

37.8392Â GBP

1p ordinary

SWAP

Long

5,559

37.6926Â GBP

1p ordinary

SWAP

Long

5,562

37.8362Â GBP

1p ordinary

SWAP

Long

11,148

37.7747Â GBP

1p ordinary

SWAP

Long

14,021

37.8546Â GBP

1p ordinary

SWAP

Long

21,411

37.8352Â GBP

1p ordinary

SWAP

Long

27,514

37.8904Â GBP

1p ordinary

SWAP

Long

27,701

37.8695Â GBP

1p ordinary

SWAP

Long

31,184

37.8856Â GBP

1p ordinary

SWAP

Short

9

37.9200Â GBP

1p ordinary

SWAP

Short

148

37.9600Â GBP

1p ordinary

SWAP

Short

302

37.8768Â GBP

1p ordinary

SWAP

Short

392

37.8359Â GBP

1p ordinary

SWAP

Short

456

37.8662Â GBP

1p ordinary

SWAP

Short

540

37.8154Â GBP

1p ordinary

SWAP

Short

694

37.8428Â GBP

1p ordinary

SWAP

Short

1,346

37.8856Â GBP

1p ordinary

SWAP

Short

2,700

37.8586Â GBP

1p ordinary

SWAP

Short

4,813

37.9754Â GBP

1p ordinary

SWAP

Short

5,000

37.9189Â GBP

1p ordinary

SWAP

Short

9,701

37.9014Â GBP

1p ordinary

SWAP

Short

10,000

37.9030Â GBP

1p ordinary

SWAP

Short

10,000

37.7966Â GBP

1p ordinary

SWAP

Short

11,900

37.8615Â GBP

 

 

 

 

 

 

 

 

(c)

Stock-settled derivative transactions (including options)

 

(i)

Writing, selling, purchasing or varying

 

Class

Product

Writing,

Number

Exercise

Type

Expiry

Option

of

description

purchasing,

of

price

 

date

money

relevant

 

selling,

securities

per unit

 

 

paid/

security

 

varying etc

to which

 

 

 

received

 

 

 

option

 

 

 

per unit

 

 

 

relates

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(ii)

Exercising

 

 

 

 

 

 

Class of relevant

Product description

Exercising/ exercised against

Number of

Exercise price per

security

 

 

securities

unit

 

 

 

 

 

 

 

 

 

 

 

 

 

(d)

Other dealings (including subscribing for new securities)

 

Class of relevant

Nature of Dealings

Details

Price per unit (if

security

 

 

applicable)

 

 

 

 

4.

OTHER INFORMATION

(a)

Indemnity and other dealings arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding,

 

 

formal or informal, relating to relevant securities which may be an inducement to deal

 

 

or refrain from dealing entered into by the exempt principal trader making the disclosure and any party

 

to the offer or any person acting in concert with a party to the offer:

 

 

 

NONE

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between

 

 

the person making the disclosure and any other person relating to:

 

 

(i)Â the voting rights of any relevant securities under any option; or

 

 

 

(ii) the voting rights of future acquisition or disposal of any relevant securities to which

 

 

any derivative is referenced:

 

 

 

 

 

 

NONE

(c)

Attachments

 

 

 

 

 

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

03 Oct 2023

Contact name:

Large Holdings Regulatory Operations

Telephone number:

020 3134 7213

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETEADEDEADDFFA
Date   Source Headline
20th Nov 20232:41 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
20th Nov 20232:33 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
20th Nov 20232:30 pmRNSForm 8.3 - Dechra Pharmaceutical PLC
20th Nov 202312:22 pmRNSForm 8.5 (EPT/NON-RI) Dechra Pharmaceuticals Plc
20th Nov 202312:19 pmGNWForm 8.3 - Dechra Pharmaceuticals PLC
20th Nov 202311:55 amRNSForm 8.3 - Dechra Pharmaceuticals
20th Nov 202311:40 amRNSForm 8.3 - Dechra Pharmaceuticals plc
20th Nov 202310:11 amRNSForm 8.5 (EPT/RI)
20th Nov 202310:11 amRNSForm 8.5 (EPT/NON-RI)
20th Nov 20239:19 amRNSForm 8.5 (EPT/RI)-Dechra Pharmaceuticals plc
20th Nov 20239:00 amRNSForm 8.3 - Dechra Pharmaceuticals plc
20th Nov 20238:56 amRNSForm 8.3 - Dechra Pharmaceuticals plc
20th Nov 20238:06 amGNWForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc
20th Nov 20237:00 amRNSForm 8.3 - Dechra Pharmaceuticals plc
17th Nov 20233:45 pmRNSHolding(s) in Company
17th Nov 20233:20 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
17th Nov 20232:49 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
17th Nov 20231:50 pmGNWForm 8.3 - Dechra Pharmaceuticals plc
17th Nov 20231:42 pmEQSForm 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
17th Nov 20231:41 pmRNSForm 8.5 (EPT/RI)- Replacement of Dechra
17th Nov 202312:17 pmRNSForm 8.3 - DECHRA PHARMACEUTICALS PLC
17th Nov 202312:03 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
17th Nov 202310:14 amRNSForm 8.5 (EPT/RI)
17th Nov 202310:13 amRNSForm 8.5 (EPT/NON-RI)
17th Nov 20239:34 amRNSForm 8.5 (EPT/RI)- Dechra Pharmaceuticals plc
17th Nov 20239:28 amRNSForm 8.3 - Dechra Pharmaceuticals plc
17th Nov 20239:21 amRNSForm 8.5 (EPT/NON-RI) Dechra Pharmaceuticals Plc
17th Nov 20239:07 amRNSForm 8.3 - Dechra Pharmaceuticals plc
17th Nov 20237:41 amGNWForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc
16th Nov 20235:11 pmRNSHolding(s) in Company
16th Nov 20233:30 pmRNSForm 8.3 - DPH LN
16th Nov 20233:29 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Nov 20233:09 pmGNWForm 8.3 - Dechra Pharmaceuticals plc
16th Nov 20233:09 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Nov 20233:05 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Nov 20232:37 pmRNSForm 8.3 - DECHRA PHARMACEUTICALS PLC
16th Nov 20232:08 pmRNSHolding(s) in Company
16th Nov 20231:49 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Nov 20231:16 pmEQSForm 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
16th Nov 202311:22 amRNSForm 8.5 (EPT/NON-RI) Dechra Pharmaceuticals Plc
16th Nov 202310:19 amRNSForm 8.5 (EPT/RI)
16th Nov 202310:18 amRNSForm 8.5 (EPT/NON-RI)
16th Nov 20239:58 amRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Nov 20239:23 amRNSForm 8.5 (EPT/RI)- Dechra Pharmaceuticals plc
16th Nov 20239:21 amRNSForm 8.5 (EPT/RI)- Dechra Pharmaceuticals plc
16th Nov 20238:41 amGNWForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc
15th Nov 20233:30 pmRNSForm 8.3 - DPH LN
15th Nov 20233:23 pmRNSForm 8.3 -DECHRA PHARMACEUTICALS PLC
15th Nov 20233:20 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Nov 20232:57 pmRNSForm 8.3 - Dechra Pharmaceuticals PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.